Published in final edited form as:

Science. 2018 April 20; 360(6386): 278–279. doi:10.1126/science.aas9268.

Insurance coverage for genomic tests

Kathryn A. Phillips^{1,2,3}, Julia R. Trosman⁴, Patricia A. Deverka^{1,5}, Bruce Quinn⁶, Sean Tunis⁷, Peter J. Neumann⁸, James D. Chambers⁸, Louis P. Garrison Jr.⁹, Michael P. Douglas¹, and Christine B. Weldon⁴

¹Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco CA 94143, USA

²Philip R. Lee Institute for Health Policy, San Francisco, CA 94118, USA

³Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA

⁴Center for Business Models in Healthcare, Northwestern University Feinberg School of Medicine, Chicago, IL 60611 USA

⁵American Institutes for Research, Chapel Hill, NC 27517, USA

⁶Bruce Quinn Associates, Los Angeles, CA 90036, USA

⁷Center for Medical Technology Policy (CMTP), Baltimore, MD 21202, USA

⁸The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA

⁹The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA

On 16 March, the Centers for Medicare and Medicaid Services (CMS) announced that Medicare will cover Food and Drug Administration (FDA)–approved or cleared genomic tests that encompass broad gene panels for advanced cancer patients (1). The final policy does not include the initial draft’s proposed “coverage with evidence development” (CED)—i.e., coverage of tests run as part of clinical trials and registries—which some had argued should be applied to develop a stronger evidence base for these tests (2). Instead, tests not already approved in the national coverage determination can be reviewed for coverage by local Medicare Administrative Contractors (MACs). The new policy reflects a substantial shift in determining how genomic tests are evaluated for coverage, which provides a needed “roadmap” for coverage. However, to develop effective and efficient policies, stakeholders should support further research to address how the new policy will affect ongoing cancer research as well as the access to and affordability of next-generation sequencing testing for cancer patients.

The new policy has the potential to increase access to testing, but it may remain out of reach for many patients. Private payers may not follow the CMS policy for covered tests, as there

*Corresponding author: kathryn.phillips@ucsf.edu.

are myriad reasons that payers have limited their coverage for broad genomic tests (3), and private payers often do not use Medicare policies as precedents (4). The tests that remain uncovered by CMS may not be covered by local MACs either (5). The numerous laboratories that offer their own tests that do not currently meet the coverage requirements in the new policy may have trouble finding the trial participants and funding they need to obtain the evidence required. Although CMS's policy may spur these laboratories to develop evidence even without a CED requirement, this process may take several years, and its outcome is uncertain (4). The CMS policy is binding only on Medicare; it is uncertain whether states will cover these tests for Medicaid patients (6).

Likewise, the policy may increase affordability and equity for these tests, but with caveats. Benefit-cost tradeoffs were not examined as they are outside the scope of CMS. CMS is caught in an ongoing dilemma: Coverage policies are determined irrespective of cost, yet there is a constant drumbeat of calls to reduce Medicare expenditures (8). Lastly, it will be important to understand the implications of the new policy for genomic tests for patients with other types of cancer and with other conditions, which face similar challenges to coverage (9).

Given today's challenging health policy environment, CMS should work with stakeholders, including other federal agencies, to carefully evaluate the benefits and risks of this novel coverage approach and to consider what additional policy mechanisms will be needed to ensure that the necessary evidence is generated. We must address the substantial uncertainty about the impact of coverage policies on the health outcomes of Medicare beneficiaries.

Acknowledgments

This letter was funded by grants from the National Human Genome Research Institute (R01 HG007063 and U01 HG009599) and by the Helen Diller Family Comprehensive Cancer Center Support Grant of the National Institutes of Health under Award Number P30 CA082103-18.

References

1. CMS. Decision Memo for Next-Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450N). 2018. www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=290&DocID=CAG-00450N&bc=AAAAAAAAQAAA&
2. Eisenberg R, Varmus H. *Science*. 2017; 358:1133. [PubMed: 29191895]
3. Phillips KA, et al. *Nat Biotechnol*. 2017; 35:614. [PubMed: 28700544]
4. Chambers JD, Chenoweth M, Thorat T, Neumann PJ. *Health Aff (Millwood)*. 2015; 34:1376. [PubMed: 26240252]
5. Levinson, DR. Local coverage determinations create inconsistency in Medicare coverage. 2014. <https://oig.hhs.gov/oei/reports/oei-01-11-00500.pdf>
6. Schattner, E. Medicare will cover genetic cancer testing, with caveats. *Forbes*. 2018. www.forbes.com/sites/elaineschattner/2018/03/16/medicare-will-cover-genetic-cancer-testing-with-caveats/#d78931d9e556
7. Neumann PJ, Chambers JD. *N Engl J Med*. 2012; 367:1775. [PubMed: 23113832]
8. Trosman JR, et al. *J Natl Compr Canc Netw*. 2017; 15:219. [PubMed: 28188191]